News
MRK-WI
73.00
0.00%
0.00
U.S. RESEARCH ROUNDUP-EQT, Las Vegas Sands, Twilio
Reuters · 43m ago
MERCK & CO INC <MRK.N>: JP MORGAN RAISES TARGET PRICE TO $135 FROM $125
Reuters · 4h ago
LIVE MARKETS-Big pharma goes on a shopping spree
Reuters · 3d ago
Merck starts pivotal Phase 2b/3 MALBEC trial of MK-8748 for wet AMD
Reuters · 3d ago
EU approves Merck Keytruda-paclitaxel regimen for PD-L1+ platinum-resistant ovarian cancer
Reuters · 3d ago
EUROPEAN COMMISSION APPROVES KEYTRUDA® (PEMBROLIZUMAB) PLUS PACLITAXEL ± BEVACIZUMAB FOR THE TREATMENT OF ADULTS WITH PD-L1 (CPS ≥1) PLATINUM-RESISTANT RECURRENT OVARIAN CARCINOMA WHO HAVE RECEIVED ONE OR TWO PRIOR SYSTEMIC TREATMENT REGIMENS
Reuters · 3d ago
Merck to host first-quarter sales and earnings conference call
Reuters · 4d ago
INFINIMMUNE ENTERS COLLABORATION WITH MERCK TO DISCOVER NOVEL HUMAN ANTIBODY THERAPEUTICS
Reuters · 5d ago
INFINIMMUNE: ELIGIBLE TO RECEIVE MILESTONE PAYMENTS FROM MERCK ASSOCIATED WITH PROGRESS OF MULTIPLE ANTIBODY CANDIDATES TOTALING UP TO ABOUT $838 MLN
Reuters · 5d ago
INFINIMMUNE: UNDER AGREEMENT, MERCK WILL HAVE EXCLUSIVE RIGHT TO DEVELOP AND COMMERCIALIZE ANTIBODY CANDIDATES
Reuters · 5d ago
U.S. RESEARCH ROUNDUP-Dutch Bros, Phreesia, Starbucks
Reuters · 6d ago
MERCK & CO INC <MRK.N>: JEFFERIES RAISES TARGET PRICE TO $138 FROM $132
Reuters · 6d ago
Merck oral PCSK9 inhibitor enlicitide cuts LDL-C 64.6% in Phase 3 AddOn trial
Reuters · 6d ago
MERCK & CO INC - ENLICITIDE SAFETY PROFILE CONSISTENT WITH PREVIOUS TRIALS, NO MEANINGFUL DIFFERENCES IN ADVERSE EVENTS
Reuters · 6d ago
Merck says Phase 2 CADENCE shows WINREVAIR cuts PVR in CpcPH-HFpEF
Reuters · 03/29 15:45
MERCK & CO: TOTALITY OF EVIDENCE ACROSS HEMODYNAMIC, FUNCTIONAL, ECHOCARDIOGRAPHIC AND CLINICAL ENDPOINTS SUPPORTS ADVANCING DEVELOPMENT OF WINREVAIR
Reuters · 03/29 15:45
MERCK & CO INC - WINREVAIR TO ADVANCE INTO REGISTRATIONAL PHASE 3 PROGRAM IN CPCPH-HFPEF
Reuters · 03/29 15:45
POSITIVE DATA FROM PHASE 2 CADENCE TRIAL PROVIDES DEFINITIVE PROOF-OF-CONCEPT FOR WINREVAIR™ (SOTATERCEPT-CSRK) IN ADULTS WITH THE SYNDROME OF COMBINED POST- AND PRECAPILLARY PULMONARY HYPERTENSION AND HEART FAILURE WITH PRESERVED EJECTION FRACTION
Reuters · 03/29 15:45
Global New Material International FY2025 revenue jumps 76.9% to RMB2.9 billion; operating income drops to RMB132,884,000 due to higher finance costs
Reuters · 03/27 14:41
TERNS PHARMACEUTICALS SHARES UP 5% ON MERCK'S $6.7 BILLION TAKEOVER DEAL
Reuters · 03/25 13:31
More
Webull provides a variety of real-time MRK-WI stock news. You can receive the latest news about MERCK & CO through multiple platforms. This information may help you make smarter investment decisions.
About MRK-WI
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.